A novel reaction mediated by human aldehyde oxidase: Amide hydrolysis of GDC-0834

Drug Metabolism and Disposition

Volumn 43, Issue 6, 2015, Pages 908-915

  Sodhi, Jasleen K ^a   Wong, Susan ^a   Kirkpatrick, Donald S ^a   Liu, Lichuan ^a   Khojasteh, S Cyrus ^a   Hop, Cornelis E C A ^a   Barr, John T ^b   Jones, Jeffrey P ^b   Halladay, Jason S ^a,c  

^a GENENTECH INC   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; AMIDE; BRUTON TYROSINE KINASE INHIBITOR; CARBOXYLESTERASE; HYDROXYL GROUP; N [3 [6 [4 (1,4 DIMETHYL 3 OXOPIPERAZIN 2 YL) PHENYLAMINO] 4 METHYL 5 OXO 4,5 DIHYDROPYRAZIN 2 YL] 2 METHYLPHENYL] 4,5,6,7 TETRAHYDROBENZO[B] THIOPHENE 2 CARBOXAMIDE; UNCLASSIFIED DRUG; XANTHINE OXIDASE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; AOX1 PROTEIN, HUMAN; N-(3-(6-(4-(1,4-DIMETHYL-3-OXOPIPERAZIN-2-YL)PHENYLAMINO)-4-METHYL-5-OXO-4,5-DIHYDROPYRAZIN-2-YL)-2-METHYLPHENYL)-4,5,6,7-TETRAHYDROBENZO(B)THIOPHENE-2-CARBOXAMIDE; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINONE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; BINDING SITE; COMPUTER MODEL; CYTOSOLIC FRACTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG HYDROLYSIS; DRUG METABOLISM; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER CELL; LIVER CYTOSOL; MASS SPECTROMETRY; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEOMICS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; BLOOD; CHEMISTRY; CONFORMATION; CYTOSOL; DRUG STABILITY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; ENZYMOLOGY; GENE EXPRESSION PROFILING; HYDROLYSIS; KINETICS; LIVER; METABOLISM; MOLECULAR DOCKING; MOLECULAR MODEL;

ALDEHYDE OXIDASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCATALYSIS; CATALYTIC DOMAIN; CYTOSOL; DRUG STABILITY; DRUGS, INVESTIGATIONAL; GENE EXPRESSION PROFILING; HUMANS; HYDROLYSIS; KINETICS; LIVER; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINONES; SUBSTRATE SPECIFICITY; THIOPHENES;

EID: 84940398406     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061804     Document Type: Article

References (34)

1. Alfaro JF and Jones JP (2008) Studies on the mechanism of aldehyde oxidase and xanthine oxidase. J Org Chem 73:9469-9472.
2. Baker BR and Wood WF (1967) Irreversible enzyme inhibitors. CII. On the mode of phenyl binding of 9-phenylguanine to guanine deaminase and xanthine oxidase. J Med Chem 10: 1101-1105.
3. Barr JT and Jones JP (2011) Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab Dispos 39:2381-2386.
4. Barr JT and Jones JP (2013) Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. Drug Metab Dispos 41:24-29.
5. Beedham C (2002) Molybdenum hydroxylases, in Enzyme Systems that Metabolise Drugs and Other Xenobiotics (Ionnides C, ed) pp 147-187, Wiley, New York.
6. Beedham C, Bruce SE, Critchley D.J., al-Tayib Y, and Rance DJ (1987) Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 12:307-310.
7. Beedham C, Bruce SE, Critchley D.J., and Rance DJ (1990) 1-substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases. Biochem Pharmacol 39: 1213-1221.
8. Beedham C, Critchley DJ, and Rance DJ (1995) Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon. Arch Biochem Biophys 319:481-490.
9. Coelho C, Mahro M, Trincão J, Carvalho A.T., Ramos MJ, Terao M, Garattini E, Leimkühler S, and Romão MJ (2012) The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity. J Biol Chem 287:40690-40702.
10. Dalvie D, Sun H, Xiang C., Hu Q, Jiang Y, and Kang P (2012) Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide. Drug Metab Dispos 40:1575-1587.
11. Hutzler JM, Yang YS, Albaugh D, Fullenwider C.L., Schmenk J., and Fisher MB (2012) Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 40:267-275.
12. Johns DG (1967) Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 46:1492-1505.
13. Johns DG, Spector T, and Robins RK (1969) Studies on the mode of oxidation of pyrazolo(3,4-d) pyrimidine by aldehyde oxidase and xanthine oxidase. Biochem Pharmacol 18:2371-2383.
14. Jones JP and Korzekwa KR (2013) Predicting intrinsic clearance for drugs and drug candidates metabolized by aldehyde oxidase. Mol Pharm 10:1262-1268.
15. Kawashima K, Hosoi K, Naruke T., Shiba T, Kitamura M, and Watabe T (1999) Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 27:422-428.
16. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
17. Liu L, Di Paolo J, Barbosa J, Rong H., Reif K, and Wong H (2011a) Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phos-phorylation and efficacy. J Pharmacol Exp Ther 338:154-163.
18. Liu L, Halladay JS, Shin Y, Wong S., Coraggio M, La H, Baumgardner M., Le H, Gopaul S, and Boggs J, et al. (2011b) Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab Dispos 39:1840-1849.
19. McAllister FE and Gygi SP (2013) Correlation profiling for determining kinase-substrate relationships. Methods 61:227-235.
20. McCracken NW, Blain PG, and Williams FM (1993) Human xenobiotic metabolizing esterases in liver and blood. Biochem Pharmacol 46:1125-1129.
21. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
22. Obach RS, Huynh P, Allen M.C., and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19.
23. Phu L, Izrael-Tomasevic A, Matsumoto M.L., Bustos D., Dynek JN, Fedorova AV, Bakalarski CE, Arnott D, Deshayes K., and Dixit VM, et al. (2011) Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals. Mol Cell Proteomics 10:003756.
24. Rivory LP, Bowles MR, Robert J, and Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111.
25. Sahi J, Khan KK, and Black CB (2008) Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2:176-183.
26. Satoh T, Hosokawa M, Atsumi R., Suzuki W, Hakusui H, and Nagai E (1994) Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664.
27. Schofield PC, Robertson IG, and Paxton JW (2000) Inter-species variation in the metabolism and inhibition of N-[(2'-dimethylamino) ethyl]acridine-4-carboxamide (DACA) by aldehyde oxi-dase. Biochem Pharmacol 59:161-165.
28. Sharma R, Eng H, Walker G.S., Barreiro G., Stepan AF, McClure KF, Wolford A, Bonin P.D., Cornelius P., and Kalgutkar AS (2011) Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma. Chem Res Toxicol 24:2207-2216.
29. Sheng Z, Zhang S, Bustos D., Kleinheinz T, Le Pichon CE, Dominguez SL, Solanoy HO, Drummond J, Zhang X., Ding X, et al. (2012) Ser1292 autophosphorylation is an pindicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 4 (164):164ra161.
30. Tabata T, Katoh M, Tokudome S., Nakajima M, and Yokoi T (2004) Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab Dispos 32:1103-1110.
31. Taketani M, Shii M, Ohura K., Ninomiya S, and Imai T (2007) Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci 81:924-932.
32. Uetrecht JP and Trager W (2007) Drug Metabolism Chemical and Enzymatic Aspects, Informa Healthcare USA, New York.
33. Weidert ER, Schoenborn SO, Cantu-Medellin N, Choughule K.V., Jones JP, and Kelley EE (2014) Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: implications for identifying molybdopterin nitrite reductases. Nitric Oxide 37:41-45.
34. Williams ET, Bacon JA, Bender D.M., Lowinger JJ, Guo WK, Ehsani ME, Wang X, Wang H., Qian YW, and Ruterbories KJ, et al. (2011) Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab Dispos 39:2305-2313.